Howard JFB, et al. - Considering the elevated risk of venous thrombotic events in people with HIV, researchers sought for overall risk estimates and estimates specific to immune status and antiretroviral medication in the Dutch ATHENA cohort of people with HIV in the Netherlands. Data from Jan 1, 2003, to April 1, 2015, included data of 14,389 people with HIV and 99,762 person-years of follow-up, with a median follow-up of 7·2 years. During this period, first venous thrombotic events was reported in 232 patients. They observed a higher risk of a venous thrombotic event in independent correlation with CD4 counts less than 200 cells per μL, a high viral load, and current or recent opportunistic adverse events. No specific antiretroviral drugs were identified to be associated with the risk of a venous thrombotic event. They observed lower rates associated with pregnancy, malignancy, and hospitalization when compared with primary thromboprophylaxis thresholds suggested by the respective guidelines. These findings do not support prescribing primary outpatient thromboprophylaxis as well as not support avoiding any type of antiretroviral medication in people with HIV at high risk of a venous thrombotic event.